U
BIB icon

UBS’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

UBS’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$177K Sell
3,400
-7,400
-69% -$359K ﹤0.01% 5318
2014
Q2 		$501K Buy
10,800
+8,400
+350% +$332K ﹤0.01% 4219
2014
Q1 		$96K Buy
+2,400
New +$109K ﹤0.01% 6018

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
ABI
Adamant Biomedical Investments Zurich, Switzerland $418M AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

UBS's BIB Position: Q3 2014 in Review

UBS sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2014, closing a stake of 218 shares — an estimated $10.6K sold.

UBS first reported a position in BIB in Q2 2013 and held it in 4 quarters. The position peaked at $129K in Q1 2014. 17 funds tracked by Wall St. Rank hold BIB as of Q3 2014.

  • UBS reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2014 after selling out during the quarter.
  • UBS sold 218 ProShares Ultra NASDAQ Biotechnology shares in Q3 2014, an estimated $10.6K.
  • UBS first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2013 and held it in 4 quarters.
  • UBS's ProShares Ultra NASDAQ Biotechnology position peaked at $129K in Q1 2014.
  • 17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.